ClinicalTrials.gov
ClinicalTrials.gov Menu

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00268450
Recruitment Status : Terminated
First Posted : December 22, 2005
Results First Posted : July 12, 2018
Last Update Posted : July 12, 2018
Sponsor:
Information provided by (Responsible Party):
Medical University of South Carolina

December 20, 2005
December 22, 2005
May 4, 2018
July 12, 2018
July 12, 2018
September 21, 2005
April 2012   (Final data collection date for primary outcome measure)
Complete Remission Rate [ Time Frame: From day of first treatment until after cycle 3 ]
Not Provided
Complete list of historical versions of study NCT00268450 on ClinicalTrials.gov Archive Site
  • Urinary Survivin Levels [ Time Frame: Baseline, week 6 and week 12 ]
  • Urinary Cytogenitics [ Time Frame: baseline and week 12 ]
  • Progression Free Survival [ Time Frame: from first treatment until time of progression or death, whichever comes first ]
  • Median Overall Surivial [ Time Frame: from first treatment until death ]
  • Percentage of Planned Dose Received [ Time Frame: from first treatment until end of week 12 ]
  • Rate of Post-operative Complications [ Time Frame: from first treatment until up to 48 hours after surgery. ]
Not Provided
Not Provided
Not Provided
 
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
A Phase II Study of Neo-Adjuvant Cisplatin, Gemcitabine & Bevacizumab, Followed by Radical Cystectomy for Patients With Muscle Invasive, Resectable, Non-Metastatic Transitional Cell Carcinoma (TCC) of the Bladder

RATIONALE: Drugs used in chemotherapy, such as cisplatin, gemcitabine, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving cisplatin, bevacizumab, and gemcitabine followed by surgery, bevacizumab, and paclitaxel works in treating patients with locally advanced nonmetastatic bladder cancer that can be removed by surgery.

Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Bladder Cancer
  • Biological: bevacizumab

    Before surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 4 cycles

    After surgery: given as a 15mg/kg IV over 90 minutes every 21 days for 3 cycles

    Other Name: avastin
  • Drug: cisplatin
    Before surgery: given as a 70mg/m2 IV over 60 minutes every 21 days for 4 cycles
  • Drug: gemcitabine hydrochloride
    Before surgery: given as a 1000mg/m2 IV over 30 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
  • Drug: paclitaxel
    After surgery: given as a 175 mg/m2 dose ver 3 hours every 21 days for 3 cycles
  • Procedure: cysectomy
Experimental: study intervention
Neo-adjuvant cisplatin, gemcitabine and bevacizumab followed by radical cystectomy. Patients without residual disease will enter follow up after surgery. Patients with residual disease will receive adjuvant therapy with bevacizumab and ciaplatin.
Interventions:
  • Biological: bevacizumab
  • Drug: cisplatin
  • Drug: gemcitabine hydrochloride
  • Drug: paclitaxel
  • Procedure: cysectomy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
21
Not Provided
April 2012
April 2012   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed transitional cell cancer (TCC) of the bladder

    • Staged as follows:

      • Muscle invasive (T2-T4a)
      • Node negative (N0)

        • No histologically or cytologically proven lymph node metastases
      • Nonmetastatic (M0)

        • No evidence of distant metastases
  • Resectable disease
  • Able to begin protocol treatment within 6 weeks after transurethral resection and cystoscopic evaluation
  • No central nervous system or brain metastases

PATIENT CHARACTERISTICS:

  • ECOG performance status of 0-2
  • Karnofsky 60-100%
  • White blood cell count ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • AST(SGOT) and ALT(SGPT) ≤ 2 times upper limit of normal
  • Bilirubin ≤1.5 mg/dL
  • Creatinine clearance ≥ 60 mL/min
  • Urine protein/creatinine ratio < 1.0
  • Blood pressure ≤150/100 mm Hg
  • No prohibitive medical risks for chemotherapy
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to cisplatin, gemcitabine hydrochloride, or paclitaxel
  • No unstable angina
  • No history of myocardial infarction within the past 6 months
  • No cardiac arrhythmias
  • No New York Heart Association (NYHA) congestive heart failure ≥ grade 2
  • No history of stroke within the past 6 months
  • No clinically significant peripheral vascular disease
  • No evidence of bleeding diathesis or coagulopathy
  • No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
  • No serious nonhealing wound, ulcer, or bone fracture
  • No psychiatric illness or other psychosocial situation that would limit ability to comply with study and/or follow-up procedures
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must agree to use adequate contraception prior to study entry and for the duration of study participation
  • No significant traumatic injury with in the past 28 days

PRIOR CONCURRENT THERAPY:

  • No prior systemic chemotherapy
  • No prior pelvic radiation therapy
  • More than 4 weeks since prior participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
  • No concurrent participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
  • No major surgical procedure or open biopsy within the past 28 days
  • No anticipation of need for major surgical procedure during the course of the study
  • No minor surgical procedures, fine-needle aspirations, or core biopsies within the past 7 days
  • No concurrent treatment with hormones or other chemotherapeutic agents except the following:

    • Steroids given for adrenal failure
    • Hormones administered for nondisease-related conditions (e.g., insulin for diabetes)
    • Intermittent use of dexamethasone as an antiemetic in solid tumor protocols
  • No other concurrent investigational or commercial agents or therapies
Sexes Eligible for Study: All
18 Years to 120 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00268450
CDR0000454937
MUSC-AVF-3312
MUSC-HR-15537
GENENTECH-AVF-3312
MUSC-CTO-100892
Yes
Not Provided
Not Provided
Medical University of South Carolina
Medical University of South Carolina
Not Provided
Study Chair: Andrew S. Kraft, MD Medical University of South Carolina
Study Chair: Gustavo Leone Medical University of South Carolina, Hollings Cancer Center
Medical University of South Carolina
May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP